Glimicure 2 Tablet contains Glimepiride 2 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. Glimepiride acts by stimulating insulin secretion from pancreatic beta cells, thereby improving glycemic control in patients with inadequate response to diet and exercise alone. It enhances insulin sensitivity and promotes peripheral glucose uptake, contributing to reduced blood glucose levels. Glimicure 2 is typically prescribed as part of a comprehensive diabetes management plan, including dietary modifications and physical activity. The tablet is administered once daily, preferably with breakfast, to optimize efficacy and minimize the risk of hypoglycemia. Caution is advised in patients with hepatic or renal impairment, and it should be used with care in elderly patients due to increased susceptibility to hypoglycemic episodes. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and allergic skin reactions. Regular monitoring of blood glucose levels and periodic assessment of renal and hepatic function are recommended during therapy. Glimicure 2 should not be used in patients with type 1 diabetes, diabetic ketoacidosis, or hypersensitivity to sulfonylureas. Consultation with a healthcare professional is essential before initiating treatment to ensure appropriate dosing and to manage potential drug interactions.